Trial Profile
Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Vinflunine (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms Jasint-2
- Sponsors Pierre Fabre
- 25 Oct 2019 Status changed from recruiting to completed.
- 13 Jun 2019 This trial was completed in UK, according to European Clinical Trials Database
- 10 Nov 2018 This trial has been discontinued in France (End date: 2016-07-26) .